CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+T-cell counts >200 cells/mm3

被引:0
|
作者
Guiguet, Marguerite [1 ,2 ]
Kendjo, Eric [1 ,2 ]
Carcelain, Guislaine [3 ]
Abgrall, Sophie [4 ]
Mary-Krause, Murielle [1 ,2 ]
Tattevin, Pierre [5 ]
Yazdanpanah, Yazdan [6 ]
Cotagliola, Dominique [1 ,2 ]
Duval, Xavier [7 ]
机构
[1] INSERM, U943, Paris, France
[2] Univ Paris 06, UMR S943, Paris, France
[3] Hop La Pitie Salpetriere, AP HP, Paris, France
[4] Hop Avicenne, AP HP, F-93009 Bobigny, France
[5] CHU Pontchaillou, Rennes, France
[6] CHU Tourcoing, Tourcoing, France
[7] Hop Bichat Claude Bernard, APHP, F-75877 Paris, France
关键词
HIV-INFECTED PATIENTS; DISEASE PROGRESSION; AQUITAINE COHORT; BASE-LINE; THERAPY; CD4+; DETERMINANTS; INDIVIDUALS; LYMPHOCYTES; RISK;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The aim of this study was to evaluate the clinical prognostic value of the CD4(+) T-cell percentage (%CD4), the CD4(+)/CD8(+) T-cell ratio or the CD8(+) T-cell count, in addition to the CD4(+) T-cell count and viral load (VL) in antiretroviral-naive HIV-infected patients with CD4(+) T-cell counts >200 cells/mm(3). Methods: Antiretroviral-naive patients (n=9,740) who were AIDS-free and had a CD4(+) T-cell count >200 cells/mm(3) at their first visit after January 1997 were followed-up until treatment initiation or clinical progression (mean follow-up 17 months and 13,660 person-years). Poisson regression was used for statistical analyses. Results: Progression to AIDS-defining events (ADEs), serious ADEs and death occurred in 228 patients (crude rate 1.69 per 100 person-years), 105 patients (0.77 per 100 person-years) and 67 patients (0.49 per 100 person-years), respectively. Regarding progression to ADE, the data fit was improved when the model also included the %CD4 (Akaike's information criteria [AIC] 2,049) and, to a lesser extent, the CD4(+)/CD8(+) T-cell ratio (AIC 2,053), in addition to CD4(+) T-cell count and VL (AIC 2,056). After adjustment for VL and baseline characteristics, patients with CD4+ T-cell counts of 350-500 cells/mm(3) and %CD4<15% had an estimated incidence of ADE of 3 per 100 person-years, similar to that in patients with CD4+ T-cell counts of 200-350 cells/mm(3) and %CD4>15%. The %CD4 was also significantly associated with the risk of serious ADE. By contrast, %CD4, CD4(+)/CD8(+) T-cell ratio or CD8(+) T-cell count had no additional prognostic value for the risk of death. Conclusions: In antiretroviral-naive HIV-infected patients with CD4(+) T-cell counts >200 cells/mm(3), the %CD4 was predictive of the risk of clinical progression independently of CD4(+) T-cell count and VL.
引用
收藏
页码:451 / 457
页数:7
相关论文
共 50 条
  • [1] Short Communication Factors Influencing Time to CD4+ T Cell Counts &gt;200 Cells/mm3 in HIV-Infected Individuals with CD4+ T Cell &lt;50 Cells/mm3 at the Time of Starting Combination Antiretroviral Therapy
    Ku, Nam Su
    Song, Young Goo
    Han, Sang Hoon
    Kim, Sun Bean
    Kim, Hye-won
    Jeong, Su Jin
    Kim, Chang Oh
    Kim, June Myung
    Choi, Jun Yong
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2012, 28 (12) : 1594 - 1597
  • [2] Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts ≥200 cells/mm3
    Lapadula, Giuseppe
    Torti, Carlo
    Maggiolo, Franco
    Casari, Salvatore
    Suter, Fredy
    Minoli, Lorenzo
    Pezzoli, Chiara
    Di Pietro, Massimo
    Migliorino, Guglielmo
    Quiros-Roldan, Eugenia
    Ladisa, Nicoletta
    Sighinolfi, Laura
    Costarelli, Silvia
    Carosi, Giampiero
    ANTIVIRAL THERAPY, 2007, 12 (06) : 941 - 947
  • [3] AIDS-associated paracoccidioidomycosis in a patient with a CD4+T-cell count of 4 cells/mm3
    Contente Nogueira, Lisiane Machado
    Santos, Monica
    de Lima Ferreira, Luiz Carlos
    Talhari, Carolina
    Rodrigues, Rodrigo Ribeiro
    Talhari, Sinesio
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2011, 86 (04) : 129 - 132
  • [4] Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection
    Carotenuto, P
    Looij, D
    Keldermans, L
    de Wolf, F
    Goudsmit, J
    AIDS, 1998, 12 (13) : 1591 - 1600
  • [5] Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts &gt;200 cells/mm3
    Toulson, AR
    Harrigan, R
    Heath, K
    Yip, B
    Brumme, ZL
    Harris, M
    Hogg, RS
    Montaner, JSG
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (10): : 1787 - 1793
  • [6] Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function
    Fernandez, Sonia
    Price, Patricia
    McKinnon, Elizabeth J.
    Nolan, Richard C.
    French, Martyn A.
    CLINICAL IMMUNOLOGY, 2006, 120 (02) : 163 - 170
  • [7] Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of &gt;350 cells/mm3:: Disease progression, treatment durability, and drug toxicity
    Sterling, TR
    Chaisson, RE
    Moore, RD
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (06) : 812 - 815
  • [8] Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts
    Mocroft, Amanda
    Staszewski, Schlomo
    Weber, Rainer
    Gatell, Jose
    Rockstroh, Jurgen
    Gasiorowski, Jacek
    Panos, George
    Monforte, Antonella d'Arminio
    Rakhmanova, Aza
    Phillips, Andrew N.
    Lundgren, Jens D.
    ANTIVIRAL THERAPY, 2007, 12 (03) : 325 - 333
  • [9] CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/μL
    Moore, D. M.
    Hogg, R. S.
    Yip, B.
    Craib, K.
    Wood, E.
    Montaner, J. S. G.
    HIV MEDICINE, 2006, 7 (06) : 383 - 388
  • [10] Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3
    Plana, M
    Garcia, F
    Oxenius, A
    Ortiz, GM
    Lopez, A
    Cruceta, A
    Mestre, G
    Fumero, E
    Fagard, C
    Sambeat, MA
    Segura, F
    Miró, JM
    Arnedo, M
    Lopalcos, L
    Pumarola, T
    Hirschel, B
    Phillips, RE
    Nixon, DF
    Gallart, T
    Gatell, JM
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (03) : 791 - 799